InMed Pharmaceuticals Inc. (INM)

The immediate outlook is defined by a massive corporate restructuring rather than organic trading momentum. The stock is currently caught in a whirlwind of merger negotiations with Mentari Therapeutics, evidenced by headlines regarding amended terms and significant financing packages designed to extend the cash runway. This creates a binary event-driven scenario where the price is likely to remain volatile until the deal structure is finalized, offering no clear directional edge for a standard swing trade. Looking further ahead, the investment case is severely compromised by a decade-long structural decline; the company has suffered seven consecutive years of negative annual returns, with the cumulative loss over the last nine years approaching 99.8%. This persistent downward trajectory suggests the market has permanently reassessed the business quality, rendering any current valuation metrics suspect. Finally, there is no income component to consider, as the company has not paid a dividend in the last five years, leaving investors exposed entirely to capital appreciation risks in a fundamentally deteriorating enterprise.